Nebion
Nebion enables the future of genomic research through precise curation and advanced analytics of public and private studies.
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
NEBION, now part of Immunai, specializes in providing advanced biomedical research solutions through its flagship product, GENEVESTIGATOR. The company serves academic researchers and industry professionals by offering deeply curated bulk tissue and single-cell transcriptomics data. Operating in the biotech and pharmatech markets, NEBION's business model revolves around subscription-based access to its data and analysis software. The company generates revenue by licensing its platform to research institutions and pharmaceutical companies, enabling them to make groundbreaking discoveries and advancements in their fields.
Keywords: biomedical research, transcriptomics, single-cell data, bulk tissue data, GENEVESTIGATOR, academic research, industry professionals, biotech, pharmatech, data curation.